Herantis Pharma Oyj (HRTIS.HE)
EUR 1.4
(2.57%)
EUR 1.4
(2.57%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 29.84 Thousand EUR | -99.32% |
| 2022 | 439.08 Million EUR | 6882.5% |
| 2021 | 6.28 Million EUR | 5.85% |
| 2020 | 5.94 Million EUR | -17.56% |
| 2019 | 7.2 Million EUR | 22.58% |
| 2018 | 5.87 Million EUR | -2.39% |
| 2017 | 6.02 Million EUR | -24.88% |
| 2016 | 8.01 Million EUR | 6.74% |
| 2015 | 7.51 Million EUR | 19.62% |
| 2014 | 6.27 Million EUR | 239.36% |
| 2013 | 1.85 Million EUR | 10.21% |
| 2012 | 1.67 Million EUR | 34.58% |
| 2011 | 1.24 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 25 Thousand EUR | -16.24% |
| 2024 Q2 | 25 Thousand EUR | 0.0% |
| 2023 Q2 | 4.27 Million EUR | 0.0% |
| 2023 FY | 29.84 Thousand EUR | -99.99% |
| 2023 Q3 | 29.84 Thousand EUR | -99.3% |
| 2023 Q4 | 29.84 Thousand EUR | 0.0% |
| 2023 Q1 | 4.27 Million EUR | -2.71% |
| 2022 Q4 | 439.08 Million EUR | 9900.0% |
| 2022 Q3 | 4.39 Million EUR | -21.68% |
| 2022 FY | 439.08 Million EUR | 6882.5% |
| 2022 Q1 | 5.6 Million EUR | -10.85% |
| 2022 Q2 | 5.6 Million EUR | 0.0% |
| 2021 Q2 | 3.39 Million EUR | 0.0% |
| 2021 Q4 | 6.28 Million EUR | 0.0% |
| 2021 Q3 | 6.28 Million EUR | 85.5% |
| 2021 FY | 6.28 Million EUR | 5.85% |
| 2021 Q1 | 3.39 Million EUR | -42.94% |
| 2020 Q2 | 7.2 Million EUR | 0.0% |
| 2020 FY | 5.94 Million EUR | -17.56% |
| 2020 Q1 | 7.2 Million EUR | 0.0% |
| 2020 Q4 | 5.94 Million EUR | 0.0% |
| 2020 Q3 | 5.94 Million EUR | -17.56% |
| 2019 Q1 | 6.5 Million EUR | 10.59% |
| 2019 Q2 | 6.5 Million EUR | 0.0% |
| 2019 FY | 7.2 Million EUR | 22.58% |
| 2019 Q4 | 7.2 Million EUR | 0.0% |
| 2019 Q3 | 7.2 Million EUR | 10.85% |
| 2018 Q3 | 5.87 Million EUR | 3.04% |
| 2018 Q2 | 5.7 Million EUR | 0.0% |
| 2018 Q1 | 5.7 Million EUR | -5.27% |
| 2018 FY | 5.87 Million EUR | -2.39% |
| 2018 Q4 | 5.87 Million EUR | 0.0% |
| 2017 Q1 | 7.96 Million EUR | -0.65% |
| 2017 FY | 6.02 Million EUR | -24.88% |
| 2017 Q2 | 7.96 Million EUR | 0.0% |
| 2017 Q4 | 6.02 Million EUR | 0.0% |
| 2017 Q3 | 6.02 Million EUR | -24.39% |
| 2016 Q4 | 8.01 Million EUR | 0.0% |
| 2016 Q1 | 7.72 Million EUR | 2.84% |
| 2016 Q2 | 7.72 Million EUR | 0.0% |
| 2016 FY | 8.01 Million EUR | 6.74% |
| 2016 Q3 | 8.01 Million EUR | 3.79% |
| 2015 Q1 | 6.85 Million EUR | 9.14% |
| 2015 FY | 7.51 Million EUR | 19.62% |
| 2015 Q3 | 7.51 Million EUR | 9.6% |
| 2015 Q4 | 7.51 Million EUR | 0.0% |
| 2015 Q2 | 6.85 Million EUR | 0.0% |
| 2014 Q2 | 6.01 Million EUR | 218.06% |
| 2014 Q3 | 6.27 Million EUR | 4.37% |
| 2014 FY | 6.27 Million EUR | 239.36% |
| 2014 Q4 | 6.27 Million EUR | 0.0% |
| 2014 Q1 | 1.89 Million EUR | 2.23% |
| 2013 Q3 | 1.85 Million EUR | 0.0% |
| 2013 Q4 | 1.85 Million EUR | 0.0% |
| 2013 FY | 1.85 Million EUR | 10.21% |
| 2013 Q1 | 1.67 Million EUR | 0.0% |
| 2012 FY | 1.67 Million EUR | 34.58% |
| 2011 FY | 1.24 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Biohit Oyj | 400 Thousand EUR | 92.539% |
| Nanoform Finland Oyj | 5.2 Million EUR | 99.426% |